Skip to Main Content
American Flag
LABOR DAY SALE

50% off your first year of any Quiver subscription

...

Use Promo Code:

LABOR26
American Flag
×
Quiver Logo Get a Free Trial on Quiver Premium Today!
Back to News

Natera Slides as Investors Weigh Wider Loss and CEO Transition

None

Natera (NTRA) is down 6.8% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver is a continued negative reaction to Natera’s recent quarterly update, where strong revenue growth and higher full-year guidance were overshadowed by a wider-than-expected per-share loss, heavier operating spending, and an unexpected CEO transition. If this decline is occurring after the initial post-earnings selloff, it could be because investors are still repricing the stock after that mixed message.

Details:

  • Natera’s third-quarter 2026 revenue rose 34.1% year over year to $794.0 million, and the company lifted its 2026 revenue guidance to a range of $3.005 billion to $3.035 billion.
  • Despite that top-line strength, Natera posted a net loss of $59.9 million, or $0.42 per diluted share, which appears to have kept attention on profitability rather than growth.
  • Total operating expenses increased 19.5% from a year earlier, with spending tied to headcount growth, new product support, and clinical trial activity.
  • The company also disclosed a leadership change: Steve Chapman resigned as CEO and Solomon Moshkevich was appointed chief executive, adding uncertainty even though the successor came from inside the company.
  • Sources:

    SEC, Natera Investor Relations, MedTech Dive

    Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

    $NTRA Insider Trading Activity

    NTRA Insider Trades

    $NTRA insiders have traded $NTRA stock on the open market 327 times in the past 6 months. Of those trades, 0 have been purchases and 327 have been sales.

    Here’s a breakdown of recent trading of $NTRA stock by insiders over the last 6 months:

    • MATTHEW RABINOWITZ (EXECUTIVE CHAIRMAN) has made 0 purchases and 82 sales selling 309,915 shares for an estimated $95,336,819.
    • JONATHAN SHEENA has made 0 purchases and 117 sales selling 62,142 shares for an estimated $21,074,738.
    • ROELOF BOTHA has made 0 purchases and 6 sales selling 78,000 shares for an estimated $17,184,092.
    • STEVEN LEONARD CHAPMAN (CEO AND PRESIDENT) has made 0 purchases and 30 sales selling 62,436 shares for an estimated $16,407,209.
    • DANIEL RABINOWITZ (SEC. AND CHIEF LEGAL OFFICER) has made 0 purchases and 23 sales selling 54,814 shares for an estimated $14,512,417.
    • SOLOMON MOSHKEVICH (PRESIDENT, CLINICALDIAGNOSTICS) has made 0 purchases and 38 sales selling 40,027 shares for an estimated $12,750,734.
    • HERM ROSENMAN sold 16,530 shares for an estimated $4,132,500
    • MICHAEL BURKES BROPHY (CHIEF FINANCIAL OFFICER) has made 0 purchases and 15 sales selling 11,717 shares for an estimated $3,953,973.
    • JOHN FESKO (PRESIDENT, CHIEF BUS. OFFICER) has made 0 purchases and 9 sales selling 11,944 shares for an estimated $3,727,138.
    • GAIL BOXER MARCUS has made 0 purchases and 4 sales selling 11,000 shares for an estimated $2,389,328.
    • ROWAN E CHAPMAN has made 0 purchases and 2 sales selling 3,099 shares for an estimated $679,636.

    To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

    $NTRA Hedge Fund Activity

    We have seen 550 institutional investors add shares of $NTRA stock to their portfolio, and 402 decrease their positions in their most recent quarter.

    Here are some of the largest recent moves:

    To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

    $NTRA Government Contracts

    We have seen $791,200 of award payments to $NTRA over the last year.

    Here are some of the awards which we have have seen pay out the most over the last year:

    To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.

    $NTRA Analyst Ratings

    Wall Street analysts have issued reports on $NTRA in the last several months. We have seen 15 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

    Here are some recent analyst ratings:

    • Baird issued a "Outperform" rating on 11/09/2026
    • JP Morgan issued a "Overweight" rating on 11/06/2026
    • Evercore ISI Group issued a "Outperform" rating on 11/06/2026
    • BTIG issued a "Buy" rating on 10/27/2026
    • Canaccord Genuity issued a "Buy" rating on 10/19/2026
    • Morgan Stanley issued a "Overweight" rating on 10/13/2026
    • TD Cowen issued a "Buy" rating on 10/13/2026

    To track analyst ratings and price targets for $NTRA, check out Quiver Quantitative's $NTRA forecast page.

    $NTRA Price Targets

    Multiple analysts have issued price targets for $NTRA recently. We have seen 20 analysts offer price targets for $NTRA in the last 6 months, with a median target of $404.0.

    Here are some recent targets:

    • Catherine Ramsey from Baird set a target price of $403.0 on 11/09/2026
    • Casey Woodring from JP Morgan set a target price of $405.0 on 11/06/2026
    • Daniel Markowitz from Evercore ISI Group set a target price of $400.0 on 11/06/2026
    • Mark Massaro from BTIG set a target price of $430.0 on 10/27/2026
    • Kyle Mikson from Canaccord Genuity set a target price of $500.0 on 10/19/2026
    • Tejas Savant from Morgan Stanley set a target price of $435.0 on 10/13/2026
    • Dan Brennan from TD Cowen set a target price of $480.0 on 10/13/2026

    This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.

    Add Quiver Quantitative to your preferred sources on Google Google News Logo

    Suggested Articles